knowledge -WSS

knowledge

author：leisure time 2025-08-23 03:45:44 - browse：4

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Congress must give Medicare recipients genetic counseling access

WSS

What the US credit downgrade means for the economy, your finances

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Baltimore teen accused of firing into crowd during block party mass shooting

Trump cancels press conference intended to dispute Georgia election interference charges

Listen: Racing for gene therapy & a pioneering approval

Hilary may become 1st tropical storm to make landfall in California in 84 years

knowledge

knowledge

knowledge

Supreme Court strikes down use of affirmative action

ProMED sees offers of support, but its future remains unclear

Virginia high school admissions case could be legal follow

Mega Millions pot grows to $1.25 billion after no winner

BioMarin wins approval for gene therapy to treat hemophilia A

New safety details link Apellis eye drug to rare cases of blindness

Hollywood unions extend contract negotiations for actors

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Dobbs anniversary: the lost opportunity of abortion as health care

Clinical trials must include more disabled people

hotspot

Lawsuit alleges UnitedHealth Group unit illegally denied claims

New safety details link Apellis eye drug to rare cases of blindness

New details revealed about Purdue's marketing of OxyContin

FDA approves first treatment for ultra

NIH launches clinical trials and new research office for long Covid

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

explore

Wikipedia

hotspot

leisure time